Fmr LLC Acquires 189,714 Shares of Pharvaris (NASDAQ:PHVS)

FMR LLC grew its holdings in Pharvaris (NASDAQ:PHVS - Free Report) by 3.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,395,370 shares of the company's stock after purchasing an additional 189,714 shares during the quarter. FMR LLC owned about 10.32% of Pharvaris worth $103,429,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of Pharvaris by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock worth $735,000 after acquiring an additional 1,356 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after buying an additional 2,847 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Pharvaris during the 4th quarter worth approximately $111,000. Palumbo Wealth Management LLC acquired a new stake in Pharvaris in the 4th quarter valued at $196,000. Finally, Barclays PLC bought a new stake in Pharvaris in the third quarter valued at $106,000.

Pharvaris Stock Performance

Pharvaris stock traded up $0.28 on Friday, reaching $14.00. The company's stock had a trading volume of 10,082 shares, compared to its average volume of 69,485. The business's fifty day moving average price is $15.13 and its 200 day moving average price is $18.19. The company has a market cap of $732.06 million, a price-to-earnings ratio of -5.00 and a beta of -2.84. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Monday, April 7th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06. As a group, equities analysts forecast that Pharvaris will post -2.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities lifted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.